Study of Injectable Hydrogel Based on ALN/Nha Promoting Osteogenesis And Inhibiting Osteoclasts in Osteoporotic Bone Defects Repair.

Osteoporotic bone defects cannot withstand surgery with more significant trauma due to bone fragility, while systemic drug therapy has formidable adverse effects. Consequently, the present study introduces an innovatively devised injectable double-crosslinked hydrogel, as a potential therapeutic avenue for addressing varied shapes of osteoporotic bone defects via a minimally invasive approach. The injectable hydrogel was formed by the formation of Schiff base bonds between oxidized sodium alginate (OSA) and carboxymethyl chitosan, and the polymerization of gelatin methacrylate by ultraviolet light crosslinking. Additionally, alendronate sodium (ALN) was loaded into the hydrogel through Schiff base formation with OSA, and nanohydroxyapatite (nHA) was incorporated into the hydrogel via blending. The hydrogel demonstrated excellent injectability, and the nHA improved the mechanical property of hydrogel and can promote bone formation. In addition, the hydrogle can sustain release of ALN, which has the effect of inhibiting osteoclast. Cell studies indicated that the hydrogel can promote the differentiation of osteoblasts and inhibit the activity osteoclast, so as to obtain better osteogenic effect. Therefore, the injectable hydrogel can be used to repair osteoporotic bone defects through a minimally invasive, simple treatment modality. This article is protected by copyright. All rights reserved.